These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
41 related articles for article (PubMed ID: 39060055)
1. Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer. Cai C; Zhang P; Han Y; Shen H; Zeng S Lancet Gastroenterol Hepatol; 2024 Sep; 9(9):787-788. PubMed ID: 39127073 [No Abstract] [Full Text] [Related]
2. Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer - Authors' reply. Wankhede D; Hoffmeister M Lancet Gastroenterol Hepatol; 2024 Sep; 9(9):788. PubMed ID: 39127074 [No Abstract] [Full Text] [Related]
3. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692 [TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms. Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939 [TBL] [Abstract][Full Text] [Related]
5. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
6. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment. Saller J; Qin D; Felder S; Coppola D Clin Colorectal Cancer; 2020 Jun; 19(2):123-131. PubMed ID: 32171644 [TBL] [Abstract][Full Text] [Related]
7. Identification of DNA Repair-related Genes as Biomarkers Reflecting MSI, TMB, and TIL in Colorectal Cancer. Fukuda J; Sudo T; Kikuchi M; Kawahara A; Shigyo H; Kawamoto Y; Shimamura S; Koga F; Noguchi T; Nakane H; Shigaki T; Fujiyoshi K; Yomoda T; Yoshida N; Koushi K; Yoshida T; Akiba J; Fujita F Anticancer Res; 2024 Aug; 44(8):3567-3575. PubMed ID: 39060055 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640 [TBL] [Abstract][Full Text] [Related]
9. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies. Yang C; Zhao L; Lin Y; Wang S; Ye Y; Shen Z Crit Rev Oncol Hematol; 2024 Aug; 200():104204. PubMed ID: 37984588 [TBL] [Abstract][Full Text] [Related]
10. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. Tan E; Sahin IH Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189 [No Abstract] [Full Text] [Related]